
Aeglea BioTherapeutics (NASDAQ:AGLE) brought in sales totaling $1.36 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 19.51%, resulting in a loss of $24.44 million. Aeglea BioTherapeutics collected $3.64 million in revenue during Q4, but reported earnings showed a $20.45 million loss.